CHICAGO – A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests.
The findings, from one of the first studies to explore whether sequencing blood-borne DNA is a feasible approach to the early cancer detection, will be featured in a press briefing today and presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
“We’re excited that the initial results from the CCGA study show it is possible to detect early-stage lung cancer from blood samples using genome sequencing,” said lead study author Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute. “There is an unmet need globally for early-detection tests for lung cancer that can be easily implemented by health-care systems. These are promising early results and the next steps are to further optimize the assays and validate the results in a larger group of people.”
Early diagnosis is key to improving survival rates for lung cancer. A blood test that could be done through a simple blood draw at the doctor’s office could potentially have a major impact on survival, but before such a test could
Article originally posted at